Lv5
1000 积分 2022-03-21 加入
Seizing the opportune moment: early use of antiplatelet therapy for thrombolysis
16天前
已完结
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial
24天前
已完结
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
28天前
已完结
The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients
28天前
已完结
The real-world impact of biologics for NMOSD: A retrospective single-center study compared with natural course and conventional treatments in Japanese
29天前
已完结
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
1个月前
已完结
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial
1个月前
已完结
Real-World experience with efgartigimod in patients with myasthenia gravis
1个月前
已完结
Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study
1个月前
已完结
Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis
1个月前
已完结
皖公网安备34019202002308
